Novel oncolytic parvoviruses with enhanced cargo capacity, stable shRNA expression cassette and novel immunogenic properties
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 25, 2022
app pub date -
Feb 14, 2022
filing date -
Feb 12, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Novel engineered oncolytic protoparvoviruses are described to be used in cancer therapy. The engineered protoparvoviruses contain at least one deletion in the untranslated region and a silencer sequence that remains stably integrated into the viral genome during extensive virus propagation. The novel viruses can be used for the silencing of relevant cancer-related genes, providing to the virus a new anticancer mechanism of action.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully